NEW YORK – Sebia announced on Wednesday that it has acquired German diagnostic firm Orgentec Diagnostika for an undisclosed amount.
Sebia, a provider of clinical protein electrophoresis equipment and reagents for oncology and diabetes detection, acquired the company from healthcare investor Water Street Healthcare Partners. The deal is expected to close in the next quarter.
In a statement, Lisses, France-based Sebia said the acquisition will provide development opportunities and expand Sebia's capabilities in autoimmunity, infectious diseases, and clinical trials.
Mainz, Germany-based Orgentec develops and markets autoimmune and blood diagnostic tests, in addition to tests for treatment-associated monitoring. Its clinical areas include inflammatory rheumatic diseases, thrombosis, blood diagnostics for the serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology, and diabetes.
Orgentec operates Corgenix Medical, a Broomfield, Colorado-based company that helps in the development, technology transfer, registration, manufacturing, and commercialization of specialty diagnostic tests. It also operates Arotec Diagnostics, a Wellington, New Zealand-based firm that supplies reagents for autoimmune diagnostic tests.
"Orgentec, Arotec, and Corgenix have developed strong expertise in autoimmunity, infectious diseases, and clinical trials, and we see many areas for collaboration in our respective R&D programs and benefits for our global commercial network development," Sebia CEO Jean-Marc Chermette said in a statement.